Небулайзеры для длительной поддерживающей терапии обструктивных заболеваний легких

1. Tashkin DP. The Role of Nebulizers in Airways Disease Management. Touch Briefings 2007; 27–31.
2. Cochrane MG, Bala MV, Downs KE et al. Inhaled corticosteroids for asthma therapy. Patient compliance, devices, and inhalation technique. Chest 2000; 117: 542–50.
3. Huchon G. Metered dose inhalers part and present: advantages and limitations. Eur Respir Rev 1997; 7 (41): 26–8.
4. Borgstrom L, Bisgaard H, O'Callaghan C, Pedersen S. Dry-powder inhalers. Ed: Bisgaard H, O'Callaghan C, Smaldone G. Drug delivery to the lung. New York: Marcel Dekker, Inc. 2002; 421–48.
5. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96: 293–304.
6. Lavorini F, Magnan A, Dubus JC et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008; 102: 593–604.
7. Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 10 (5): 255–61.
8. Boe J, Dennis JH, O'Driscoll BR et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001; 18: 228–42.
9. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002; 47: 1406–18.
10. Vecellio L. The mesh nebulizer: a recent technical innovation for aerosol delivery. Breathe 2006; 2: 253–60.
11. Knoch M, Keller M. The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliver 2005; 2: 377–90.
12. Newman S, Gee-Turner A. The Omron MicroAir vibrating mesh technology nebuliser, a 21st century approach to inhalation therapy. J Appl Ther Res 2005; 5: 429–33.
13. Чучалин А.Г., Княжеская Н.П., Потапова М.О. «Место небулайзеров в ингаляционной терапии хронических обструктивных заболеваний лёгких». Рус. мед. журн. 2006; 14(7). 
14. Dennis J, Pieron C, Gee-Turner A et al. Omron VVT Nebulizer Performance. J Aerosol Med 2007; 20: 365–92.
15. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. Chest 2005; 127: 335–71.
16. British Thoracic Society Nebuliser Project Group. Current best practice for nebuliser treatment. Thorax 1997; 52 (Suppl. 2): S1–S24.
17. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2006, National Institutes of Health/WHO. Available from http://www.goldcopd.com.
18. ERS Task Force. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001; 18: 228–42.
19. O'Driscoll BR, Kay EA, Taylor RJ et al. A long-term prospective assessment of home nebulizer treatment. Respir Med 1992; 86: 317–25.
20. Goldman JM, Teale C, Muiers MF. Simplifying the assessment of patients with chronic airflow limitation for home nebulizer therapy. Respir Med 1992; 86: 33–8.
21. Morrison JFJ, Jones PC, Muers MF. Assessing physiological benefit from domiciliary nebulized bronchodilators in severe airflow limitation. Eur Respir J 1992; 5: 424–9.
22. Barta S, Crawford A, Roberts C. Survey of patients' views of domiciliary nebuliser treatment for chronic lung disease. Respir Med 2002; 96: 375–81.
23. Marcus P, Oppenheimer EA, Patel PA et al. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcomes. Ann Allergy Asthma Immunol 2006; 96: 736–43.
24. Tashkin D, Klein G, Colman SS et al. Comparing COPD treatment: nebulizer, metered dose inhaler and concomitant therapy. Am J Med 2007; 120: 435–41.

С.Н.Авдеев